Sort
10,766 grants matching “checkpoint inhibitor”
Therapeutic Targeting of Breast Cancer Tumor Initiating Cells
$413,297Charles M Perou · Univ Of North Carolina Chapel Hill · R01 · FY2023 · CA
Targeting Transcriptional Regulators for Immunotherapy of Acute Myeloid Leukemia
$413,286Marcin Kortylewski · Beckman Research Institute/City Of Hope · R01 · FY2019 · CA
Core B: Computational
$413,235Alan S Perelson · Beth Israel Deaconess Medical Center · P01 · FY2019 · AI
Radioimmunotherapy Combinations for B-cell Malignancy
$413,131Damian J. Green · Fred Hutchinson Cancer Center · R01 · FY2023 · CA
Reprogramming the Tumor Microenvironment in Ovarian Cancer
$413,104David D Schlaepfer · University Of California, San Diego · R01 · FY2021 · CA
Metabolic reprograming of fatty acid beta-oxidation to improve cancer immunotherapy
$413,046Xiang-Yang Wang · Virginia Commonwealth University · R01 · FY2020 · CA
Oncolytic Virus Therapeutic Responses Occur from Changes in the Glioblastoma Immune Microenvironment
$412,964E. Antonio Chiocca · Brigham And Women'S Hospital · R01 · FY2025 · NS
Targeting Oncostatin M-Receptor to Suppress Metastasis and Therapy Failure
$412,810Mark W Jackson · Case Western Reserve University · R01 · FY2021 · CA
Targeting Oncostatin M-Receptor to Suppress Metastasis and Therapy Failure
$412,810Mark W Jackson · Case Western Reserve University · R01 · FY2025 · CA
Evaluation of T follicular regulatory cells as novel cellular targets of cancer immunotherapy
$412,739Simon Eschweiler · University Of Tx Md Anderson Can Ctr · R37 · FY2025 · CA
Kinetochore Structure and Function
$412,736Institute For Cancer Research · R01 · FY2004 · GM
Oncolytic virus therapeutic responses occur from changes in the glioblastoma immune microenvironment
$412,687E. Antonio Chiocca · Brigham And Women'S Hospital · R01 · FY2023 · NS
Oncolytic virus therapeutic responses occur from changes in the glioblastoma immune microenvironment
$412,687E. Antonio Chiocca · Brigham And Women'S Hospital · R01 · FY2021 · NS
Oncolytic virus therapeutic responses occur from changes in the glioblastoma immune microenvironment
$412,687E. Antonio Chiocca · Brigham And Women'S Hospital · R01 · FY2022 · NS
Mechanisms of Immune Dysfunction and Morbid Outcome in Response to Shock/Sepsis
$412,510Alfred Ayala · Rhode Island Hospital · R35 · FY2016 · GM
Mechanism-Based Use of Chk1 Inhibitors in Pancreas Cancer
$412,452Jonathan Maybaum · University Of Michigan At Ann Arbor · R01 · FY2013 · CA
Targeted MEK inhibition to enhance immunotherapy in cholangiocarcinoma
$412,434Gregory B. Lesinski · Emory University · R01 · FY2021 · CA
Metabolic reprograming of fatty acid beta-oxidation to improve cancer immunotherapy
$412,390Xiang-Yang Wang · Virginia Commonwealth University · R01 · FY2019 · CA
Project 3: Identifying Molecular Vulnerabilities to Improve Interferon Gene Therapy in Bladder Cancer
$412,360Colin P Dinney · University Of Tx Md Anderson Can Ctr · P01 · FY2025 · CA
Novel multipronged Immunovirotherapy Approach for GBM Treatment
$412,267Evanthia Galanis · Mayo Clinic Rochester · R01 · FY2024 · CA
The replication checkpoint and genomic fidelity in skin
$412,130Paul Nghiem · University Of Washington · R01 · FY2011 · AR
WEE1 inhibition and tumor immunity
$411,600Bin Zhang · Northwestern University At Chicago · R01 · FY2022 · CA
Project 3: Chronic interferon and bile acid signaling as drivers of immunosuppression in age-related liver cancer
$411,554Susan M Kaech · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2023 · AG
Project 2: Cytoplasmic chromatin fragments (CCF) as a driver of liver cancer and target for intervention during aging
$411,553Peter D. Adams · Sanford Burnham Prebys Medical Discovery Institute · P01 · FY2023 · AG
Immunological, serologic, and imaging biomarker predictors of flare in pediatric spondyloarthritis
$411,417Pamela Fitch Weiss · Children'S Hosp Of Philadelphia · R01 · FY2021 · AR